John LaMattina
John LaMattina
billion conditions effective finding high patients people priority research suffer treatments
More than one billion people around the world suffer from neurological conditions and diseases, and finding new, more effective treatments for patients is a high priority for Pfizer research and development.
bets putting size specific
We're of a size and can do enough different things that we're not putting all our bets on one specific area,
aim areas challenges diseases experience genetic greatly improved medicines others patients recognize remain strong taking treat understanding
We recognize that many diseases we aim to treat have a strong genetic component. Additionally, we know some patients taking medicines show efficacy or experience side-effects, while others do not. Our understanding of all this has improved greatly but these areas remain as significant challenges in drug development.